Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets
Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput
How this was made
The 30-second read
Why it matters
The deal restructures ownership and introduces CVR payments tied to product milestones, influencing share valuation.
Market read
Merger news provides a clear catalyst for TBPH stock, enabling merger‑arbitrage strategies.
What to watch
Potential dilution from CVR payouts and integration risks.
Background
Theravance Biopharma, a Cayman‑incorporated biotech, is merging into Zymeworks via a merger sub, with contingent value rights for shareholders.
Ticker impact
SEC 8‑K filing discloses Theravance Biopharma's merger with Zymeworks, a material definitive agreement.
possible short‑term volatility with upside if merger terms are favorable.
First public disclosure of the transaction; traders can position on merger arbitrage.
Market effects
May affect other biotech M&A valuations and CVR structures.
Limited to US biotech investors.
Low, primarily a niche biotech event.
Counterpoint
Merger could face regulatory delays, reducing upside.
Key entities
- companyTheravance Biopharma, Inc.
Target company in the merger.
- companyZymeworks Inc.
Acquiring parent.
